DisperSol Technologies and Catalent today announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.

Catalent today announced the launch of its new OptiDose® Design Solution, a comprehensive assessment of your molecule, patient, and market, to help drive the dose design decision-making process and create successful treatments.

Leveraging Catalent’s proven GPEx® expression platform in a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line system, GPEx Lightning combines innovative technologies to further shorten drug substance development timelines.

Catalent today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.

Catalent has signed a development agreement with JOS Pharmaceuticals. Under the agreement, Catalent will undertake a feasibility study for the potential development of a licensed cannabidiol (CBD) product for use as an anesthetic premedication using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology.

Catalent today announced that it has been recognized by the Royal Society for the Prevention of Accidents (RoSPA) for demonstrating high health and safety standards.

Catalent today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs).

Catalent will develop a range of CivicaScript-owned generic drug Abbreviated New Drug Applications (ANDAs).

Experts from Catalent’s clinical supply business will speak at the upcoming DIA China 2021 Conference, being held at the Suzhou International Expo Center, from May 20 – 23.